QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance
QureTech Bio address a significant unmet medical need by developing new antibacterial agents that targets different infectious diseases including healthcare-associated infections and tuberculosis. This is done either by a direct antimicrobial effect or by potentiating existing antibiotics. The compounds are new small molecules from a well-developed chemical platform with excellent synthetic availability and desirable drug properties. The company has established a strong IPR portfolio based on separate patent applications for each of the development programs.
The company’s lead program is focused on developing a new class of antibiotics effective against multidrug resistant Gram-positive bacteria. Read more about the GmPcide program here.
The tuberculosis project is developed in partnership with Fimbrion Therapeutics and is supported by Phase I SBIR funding from NIH/NIAID.
Allow all cookies
Third Party Embeds
These cookies store information such as the number of visitors to the website, the number of unique visitors, which pages on the website have been visited, the source of the visit, etc. This data helps us to understand and analyze how well the website works. and where it needs to be improved.
From 25 May 2018, the General Data Protection Regulation (GDPR) applies as law in all EU member states.